AEON STORES (00984.HK): Circular for Very Substantial Acquisition of New Lease Further Delayed to 7 October
NewTimeSpace News: On 28 September 2026, AEON Stores (Hong Kong) Co., Limited (stock code: 00984) announced a further delay in the despatch of the circular relating to the very substantial acquisition of the new lease: as stated in the Company's announcement dated 7 September 2026, the circular containing further information on the new lease and the transactions contemplated thereunder and the notice of the extraordinary general meeting was to be despatched to shareholders no later than 28 September 2026; as the Company needs additional time to finalise certain information to be included in the circular, the expected despatch date is delayed to on or before 7 October 2026.
The circular will contain, among other things, further information on the new lease and the transactions contemplated thereunder, and the notice of the extraordinary general meeting. Shareholders and potential investors are advised to exercise caution when dealing in the Company's securities.
The announcement was signed by the Chairman in Hong Kong on behalf of the board.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- EDDING GENOR (06998.HK): GB268 Wins NMPA Nod for NSCLC, BTC Trials
- HENLIUS (02696.HK): NMPA Clears HLX105 Phase 1 Solid Tumour IND
- KLIGHT LASER: Closes New Round Led by China Fortune-Tech Capital, Expanding Deep-Ultraviolet Output
- OSMUNDA: Closes RMB 100 Million Series D Led Exclusively by Lishui Green Valley Talent Osmunda New Fund
- INNOVENT BIO (01801.HK): Sintilimab Gets First CHMP Positive Opinion for First-Line NSCLC